The Acute Renal Failure Following Use of Glycine- and Maltose-Stabilized IVIG Preparations
A Case Report
Article Sidebar
Main Article Content
Abstract
Background: Intravenous immunoglobulin (IVIG), used for immunodeficiency and autoimmune conditions, is generally well tolerated but may cause adverse effects such as acute kidney injury (AKI), especially with sucrose-containing formulations.
Case Presentation: We present the case of an 83-year-old woman with myasthenia gravis who developed severe AKI following IVIG therapy with sucrose-free products. She was initially treated with glycine-stabilized KIOVIG, followed by maltose-stabilized GENIVIG.
Results: Her serum creatinine increased from 0.70 to 3.78 mg/dL within days, requiring continuous venovenous hemodiafiltration (CVVHDF) for three weeks. The patient had no history of renal disease or exposure to nephrotoxic agents. Given the temporal relationship and absence of other causes, IVIG was identified as the likely contributor.
Conclusion: This case highlights that sucrose-free IVIG preparations may carry a risk of significant nephrotoxicity, warranting close renal monitoring regardless of stabilizer type.
Article Details
Copyright (c) 2025 Sosyal D, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. Canadain Blood Services. Globulin II. Chapter 4: Immune Globulin Products Intravenous Immune Globulın General information Contraindications. 2024. Accessed: 2025 Jul 5. Available from: https://professionaleducation.blood.ca/en/transfusion/clinical-guide/immunoglobulin-products
2. Kaverı SV, Dıetrıch G, Hurez V, Kazatchkıne MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunology. 1991;86(2):192-8. doi: 10.1111/j.1365-2249.1991.tb05794.x
3. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology. 2007;68(11):837-41. doi: 10.1212/01.wnl.0000256698.69121.45
4. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x
5. United HealthCare Services, Immune globulin (IVIG and SCIG). 2024. Accessed 2025 Jul 5. Available from: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/index/comm-plan/immune-globulin-ivig-scig-cs-07012025.pdf
6. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin: A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139-45
7. Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Front Immunol. 2018 Jun 8;9:1299. doi: 10.3389/fimmu.2018.01299
8. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: A case report and discussion of the relevant literature. Ann Hematol. 2004;83(11):661-5. doi: 10.1007/s00277-004-0895-2
9. Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med. 1987;82(4):624-9. doi: 10.1016/0002-9343(87)90110-0
10. MMWR Morb Mortal Wkly Rep. Renal insufficiency and failure associated with immune globulin intravenous therapy--United States, 1985-1998. 1999. Accessed 2025 Jul 5. Available from: https://www.cdc.gov/Mmwr/preview/mmwrhtml/mm4824a3.htm.
11. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol. 1997;8(11):1788-94. doi:10.1681/ASN.V8111788
12. Afssaps. Commission nationale de pharmacovigilance, Commission nationale de pharmacovigilance. 2006. Accessed 2025 Jul 5. Available from: https://archive.ansm.sante.fr/var/ansm_site/storage/original/application/0a04ec318d749d05cf95a86f1c92d1f3.pdf
13. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration . Clin Rev Allergy Immunol. 2005;29(3):173-84. doi: 10.1385/CRIAI:29:3:173
14. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis. 1996;27(3):451-3. doi: 10.1016/s0272-6386(96)90505-3
15. Onuigbo MAC. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study. Pharmacoepidemiology Drug Saf. 2012;21(3):320-2. doi: 10.1002/pds.2273
16. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013; 27(3):171-8. doi: 10.1016/j.tmrv.2013.05.004
17. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology. 2002 Dec 24;59(12 Suppl 6):S28-32. doi: 10.1212/wnl.59.12_suppl_6.s28
18. Welles CC, Tambra S, Lafayette RA. Hemoglobinuria and Acute Kidney Injury Requiring Hemodialysis Following Intravenous Immunoglobulin Infusion. Am J Kidney Dis. 2010;55(1):148-51. doi: 10.1053/j.ajkd.2009.06.013
19. Chacko B, John GT, Balakrishnan N, Kirubakaran MG, Jacob CK. Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail. 2006;28(2):193-5. doi: 10.1080/08860220500531286
20. Kim AS, Broide DH. Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency. Ann Allergy Asthma Immunol. 2017;118(2):231-3. doi: 10.1016/j.anai.2016.11.009